AIM ImmunoTech is trading 6.35% down at $0.22, with no clear company-specific catalyst identified for the September 10, 2026 decline.
- Latest highlighted developments focus on Ampligen, pancreatic-cancer strategy, and DURIPANC progress, with materials emphasizing clinical advancement.
- The S&P 500 is down 0.56% and Nasdaq Composite 0.79% as investors react to elevated inflation and firm Treasury yields.
- Global risk-off pressure may be amplified by small-cap biotech volatility.